When a patient fails a drug, we tend to consider what will be the next drug. Most of our clinics have patients on their second or third advanced therapy. Drug failure has become more common, not less. A question that we too rarely write in the notes is why did the last drug fail?
All News
Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:
TOGETHER-PsA at 52 weeks: ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone in PsA with overweight/obesity. n=271; open-label RCT. Joint, functional and metabolic outcomes improved. #2942 @Rheumnow #ACR26 #ACRBest https://t.co/zMNyrbAR5m
Merola et al, TOGETHER-PsA: At 52 weeks, ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone. A 28-point difference! Is addressing obesity becoming essential to optimal PsA care? @rheumnow #ACR2026 #ACRBest Abstract#2942
Bimekizumab BEATS Risankizumab in PsA 24 week results by ACR50 from H2H BE-BOLD: - wk 4 19.9% vs. 7.2% - wk 16 49.1% vs. 38% - wk 24 54.9% vs. 43.8% More fungal infx in IL17 group as expected, mild-mod Practice-changing results for PsA @RheumNow #ACRbest #ACR26 Abst2804 https://t.co/3GxVLNs1td
